(Q43291206)

English

Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma

scientific article published on 14 August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 November 2017

Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma (English)

1 reference

Europe PubMed Central

18 November 2017

phase II clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

author name string

Nobuo Shinohara

1

1 reference

Europe PubMed Central

18 November 2017

Akira Kumagai

2

1 reference

Europe PubMed Central

18 November 2017

Kouichi Kanagawa

3

1 reference

Europe PubMed Central

18 November 2017

Satoru Maruyama

4

1 reference

Europe PubMed Central

18 November 2017

Takashige Abe

5

1 reference

Europe PubMed Central

18 November 2017

Ataru Sazawa

6

1 reference

Europe PubMed Central

18 November 2017

Katsuya Nonomura

7

1 reference

Europe PubMed Central

18 November 2017

publication date

14 August 2009

1 reference

Europe PubMed Central

18 November 2017

Japanese Journal of Clinical Oncology

1 reference

Europe PubMed Central

18 November 2017

39

1 reference

Europe PubMed Central

18 November 2017

11

1 reference

Europe PubMed Central

18 November 2017

720-726

1 reference

Europe PubMed Central

18 November 2017

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Significance of COX-2 expression in human renal cell carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Significance of COX-2 expression in human renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Advanced renal cell carcinoma in which a combination of IFN-alpha and meloxicam was thought to be effective

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Metastatic renal carcinoma comprehensive prognostic system

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Renal Cell Carcinoma Induces Prostaglandin E2 and T-Helper Type 2 Cytokine Production in Peripheral Blood Mononuclear Cells

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYP089

21 January 2018

Identifiers

10.1093/JJCO/HYP089

1 reference

Europe PubMed Central

18 November 2017

1 reference

Europe PubMed Central

18 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43291206&oldid=1985716266"